baloxavir marboxil - versus control - for COVID 19 hospitalized pdf   xlsx method abbreviations

Outcome Relative effect 95%CI LoD Trt. better when I2 k (RCT/OBS) Bayesian probability Overall ROB Publication bias Degree of certainty Endpoint importance Published MA

efficacy endpoints 00

deaths 1.00 [0.02, 55.80]< 10%1 study (1/-)50.0 %some concernnot evaluable moderatecrucial-
clinical improvement (14-day) 1.50 [0.26, 8.82]> 10%1 study (1/-)67.3 %some concernnot evaluable moderateimportant-
clinical improvement (7-day) 1.00 [0.05, 18.57]> 10%1 study (1/-)50.0 %some concernnot evaluable moderateimportant-
mechanical ventilation 2.11 [0.06, 70.98]< 10%1 study (1/-)34.1 %some concernnot evaluable moderateimportant-
viral clearance by day 14 0.12 [0.01, 2.86]> 10%1 study (1/-)9.9 %some concernnot evaluable moderateimportant-
viral clearance by day 7 1.50 [0.26, 8.82]> 10%1 study (1/-)67.3 %some concernnot evaluable moderateimportant-
ICU admission 2.11 [0.06, 70.98]< 10%1 study (1/-)34.1 %some concernnot evaluable moderatenon important-

safety endpoints 00

serious adverse events 2.25 [0.38, 13.47]< 10%1 study (1/-)18.8 %some concernnot evaluable moderateimportant-

LoD: level of statistical demonstration: Statistically conclusive: statistically significant with a strict control of overall risk of type 1 error (statistically demonstrated), does not take into account the risk of bias; suggested: nominally statistically significant but without a strict control of overall risk of type 1 error; inconclusive: not nominally statistically significant; safety concerns;
Bayesian probability: Bayesian posterior probability of treatment effect (computed with a noninformative prior); ROB: risk of bias; k: number of studies; published MA: number of published meta-analysis on the same topic; degree of certainty adapted from GRADE. Trt. better when: indicates when the relative treatment effect shows that the studied treatment is better than control.